1. Introduction {#s0005}
===============

Huntington\'s disease (HD) is an autosomal dominant neurodegenerative disorder that causes motor, cognitive, and psychiatric symptoms ([@bb0015]; [@bb0145]). Historically, neuropathological and neuroimaging studies in HD focussed on the striatum, the brain area most severely affected across the course of the disease ([@bb0225]; [@bb0085]). Atrophy in brain regions outside of the striatum, and early in the course of HD, however, is of considerable interest (cortical areas: [@bb0195]; [@bb0090]; thalamus: [@bb0110]; hippocampus: [@bb0020]). The amygdala, a subcortical almond-shaped structure located deep in the medial temporal lobe, has been gaining interest because of its close functional connectivity with the striatum, the brain region most severely affected across the course of HD ([@bb0170]). Further, the amygdala has been ascribed to key cognitive and psychiatric symptoms that occur in the course of HD, including aberrant emotion recognition, regulation, and social behaviour, depression, and anxiety ([@bb0005]; [@bb0010]; [@bb0075]; [@bb0155]). Nevertheless, only few studies have investigated the involvement of the amygdala in HD, and so far, results have been inconsistent.

The first study to demonstrate amygdala abnormalities in HD compared voxel-based morphometry and manual segmentation for measuring subcortical volumes ([@bb0060]). Although the research focus was not on the amygdala, the voxel-based morphometry analysis indicated smaller amygdala volumes in symptomatic HD participants when compared to controls ([@bb0060]). A later study showed similar results in pre-symptomatic HD ([@bb0115]). In fMRI studies, pre-symptomatic and symptomatic HD participants have shown less activity in the amygdala and less connectivity between the amygdala and the fusiform face area than controls ([@bb0135]; [@bb0215]; [@bb0120]). In addition, a recent meta-analysis that investigated current evidence on brain atrophy in HD has demonstrated that smaller amygdala volumes are generally shown in pre-symptomatic HD compared to controls ([@bb0040]). Together, these studies indicate that the amygdala is affected at pre-symptomatic and symptomatic stages of HD. Of note are also findings of amygdala atrophy in Parkinson\'s disease ([@bb0035]; [@bb0025]; [@bb0095]), often used as a comparison to HD because of the mutual yet selective involvement of the basal ganglia.

In contrast to evidence that the amygdala is affected in HD, other studies have not revealed evidence for amygdala degeneration in HD. For example, using the transgenic rat model of HD, no differences in amygdala volumes were found between wild-type rats and HD rats ([@bb0070]). Similarly, in a volumetric human study, the amygdala was the only structure of seven brain areas (including the basal ganglia, hippocampus, and thalamus) that was not smaller in pre-symptomatic and symptomatic HD compared to controls ([@bb0210]). These inconsistent findings may be a result of underpowered studies due to small sample sizes, and the use of automated segmentation methods, which are insensitive to subtle and spatially complex grey matter differences between groups ([@bb0030]). Alongside inconsistent findings, no HD study has yet compared amygdala volumes between participants with pre-symptomatic HD and symptomatic HD, or related amygdala volumes to clinical symptoms.

In this paper, we report a cross-sectional analysis of amygdala volumetry in pre-symptomatic and symptomatic HD using data from the Australian-based IMAGE-HD study ([@bb0045]; [@bb0085]; [@bb0050]). In addition, we report on relationships between amygdala volumes and clinical and pathological measures, including motor and psychiatric symptoms, disease burden, and caudate and putamen volumes. Based on previous work suggesting that amygdala atrophy may occur in HD, we hypothesised that amygdala volumes would be smaller in participants with the HD gene overall (both pre-symptomatic and symptomatic), and relatively smaller for symptomatic HD than pre-symptomatic HD participants. In light of previous evidence of associations between atrophy in the striatum and sensorimotor cortex and clinical measures in HD ([@bb0040]; [@bb0200]), we hypothesised that smaller amygdala volumes would be associated with higher levels of motor, cognitive, and psychiatric symptoms, and worse disease burden scores and smaller caudate and putamen volumes.

2. Material and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

The sample consisted of 106 participants, of whom 59 were females: 35 pre-symptomatic HD, 36 symptomatic HD, and 35 healthy controls ([Table 1](#t0005){ref-type="table"}). The age of all participants ranged from 23 to 72 years old (*M* = 45.44, *SD* = 12.17), but because of the natural course of HD, the symptomatic HD group was older than the pre-symptomatic HD and control groups (*F*(2,103) = 8.94, *p* \< .001). Gender did not differ significantly between groups (*F*(2,103) = 2.31, *p* = .10). The study was approved by Monash University\'s Human Research Ethics Committee and Melbourne Health Human Research Ethics Committee, and informed written consent was obtained from each participant prior to testing.Table 1Participants\' demographic information.Table 1Pre-symptomatic HDSymptomatic HDControls*n*353635Males (%)14 (40%)21 (58%)12 (34%)Females (%)21 (60%)15 (42%)23 (66%)Mood medication (%)6 (17%)16 (44%)0Age (mean ± SD)\
(Range)41.59 ± 10.00\
(23.93--65.29)51.91 ± 9.36\
(38.99--70.84)42.63 ± 14.14\
(24.38--72.98)HADS Anxiety (mean ± SD)\
(Range)6.83 ± 3.37\
(1--14)5.47 ± 3.44\
(0--14)4.97 ± 2.81\
(0−11)HADS Depression (mean ± SD)\
(Range)2.74 ± 2.97\
(0−12)2.89 ± 2.38\
(0--8)2.23 ± 2.10\
(0--8)UHDRS TMS (mean ± SD)\
(Range)0.94 ± 1.24\
(0--4)19.47 ± 12.42\
(6--60)--\
--CAG repeats (mean ± SD)\
(Range)42.31 ± 1.97\
(39--46)43.17 ± 2.48\
(40--50)--\
--DBS (mean ± SD)\
(Range)269.70 ± 53.41\
(131.64--369.60)379.70 ± 70.02\
(258.14--556.97)-\
-[^1]

2.2. Amygdala volumetry {#s0020}
-----------------------

### 2.2.1. Image acquisition and pre-processing {#s0025}

High resolution MRI data from the IMAGE-HD study was acquired using a Siemens 3 Telsa scanner with a 32-channel head coil at the Murdoch Children\'s Research Institute (Royal Children\'s Hospital, Victoria, Australia). Acquisition parameters for the T1-weighted images consisted of 192 slices, voxel size 0.9, 0.8 mm × 0.8 mm, 9° flip angle. FOV was 320 × 320, inversion time 900 ms, TE 2.59 ms, RT 1900 ms. To allow for comparison of regional grey matter volumes, the raw MRI images were re-oriented, and re-sized using the Freesurfer imaging analysis suite (Martinos Center for Biomedical Imaging, Harvard-MIT, Boston, USA). Participant\'s images were de-identified prior to volumetric analysis to minimise any biases.

### 2.2.2. Volumetric analysis {#s0030}

The right and left amygdala was manually delineated on coronal slices using the software ANALYZE 12.0 (Mayo Clinic, Rochester, NY), and following a well validated protocol ([@bb0220]). Segmentation began at the caudal end of the amygdala and proceeded, slice by slice, rostrally until the amygdala was no longer visible. To ensure consistency of manual segmentation across each brain, each slice was displayed with the segmentations from the previous slice, which was then edited to reflect the shift in the amygdala boundary for that slice.

The total amygdala volume was calculated by summing the volume for the voxels included across all slices. To account for individual differences in head size, right and left amygdala volumes were normalised by regressing out total intracranial volume, following the residual method described by [@bb0080].

For intra-rater and inter-rater reliability for amygdala, tracing was assessed using intra-class correlation coefficient (ICC). Intra-rater reliability was determined for the right (ICC = 0.97) and left amygdala (ICC = 0.96) using ten randomly selected MRIs delineated by the same tracer (LA) on two occasions, at the beginning of the tracing period and at the end, three months later, to map any potential drift in reliability over time (ICCs were 0.89 for the right and 0.84 for the left amygdala). To establish inter-rater reliability, a different rater (YG-J) measured amygdala volumes on the same set of ten scans ICCs, and inter-rater reliabilities were 0.88 and 0.80 for right and left amygdala, respectively.

2.3. Clinical measures and measures of disease pathology {#s0035}
--------------------------------------------------------

We measured psychiatric symptoms with the Hospital Anxiety and Depression Scale (HADS; [@bb0230]), and motor symptoms with the Unified Huntington\'s Disease Rating Scale (UHDRS; [@bb0105]) total motor scores (TMS). Cognitive symptoms were measured using the Symbol Digit Modalities Test (SDMT; [@bb0180]), Stroop Word Test ([@bb0190]), and the University of Pennsylvania Smell Identification Test (UPSIT; [@bb0055]).

The HADS is a self-administered questionnaire that screens for levels of depression and anxiety, and consists of 7 items scored on a scale of 0--3. Scores above 7 on either subscale indicate significant levels of depression or anxiety. Our three groups showed similar levels of depressive symptoms, and the pre-symptomatic HD group indicated slightly higher anxiety symptoms than controls ([@bb0085]).

The SDMT is a brief measure of visuomotor speed and attention, and involves matching symbols to their corresponding numbers in 90 s. The SDMT is scored according to the number of correct answers. Next, the Stroop Word Test is a measure of processing speed, which involves naming the colour of written colour names as quickly as possible. The Stroop Word Test is scored according to number of correct words. Next, the UPSIT is a measure of odour recognition, which involves categorising different odours and is scored according to normative data. In our sample, symptomatic HD participants performed worse on the SDMT, Stroop Word Test, and UPSIT than pre-symptomatic and control participants. In addition, pre-symptomatic HD participants performed worse than controls on the SDMT, although both groups performed similarly on the UPSIT and Stroop Word Test ([@bb0085]).

The motor section of the UHDRS is an assessment of motor signs of HD by a trained examiner, and consists of 31 items scored on a range from 0 to 4, and summed for the TMS. A TMS over 5 demonstrates substantial motor signs. In our sample, the symptomatic HD group showed greater motor signs than the pre-symptomatic HD group ([@bb0085]).

We used previously acquired data from the IMAGE-HD study for measures of disease pathology, which included disease burden scores (DBS) and volumetry of the caudate nucleus and putamen ([@bb0085]) to examine the relationship between disease pathology and amygdala volumes. The DBS is an estimate of the pathological burden of HD, and is calculated based on the participant age and cytosine-guanine-adenine (CAG) repeat length (age × \[CAG repeat number − 35.5\]) ([@bb0045]; [@bb0150]). As expected, the symptomatic HD group showed greater disease burden than the pre-symptomatic HD group (*F*(1,69) = 55.17, *p* \< .001). Estimated years to diagnosis for the pre-symptomatic HD participants was calculated using the following formula: years to onset = (21.54 + EXP(9.556 − 0.146 × CAG repeat number) − age ([@bb0125]). Volumes of the caudate nucleus and putamen were not available for 3 of our pre-symptomatic and 6 of our symptomatic participants, and therefore these 9 HD participants were removed from this analysis. In the resulting sample, the symptomatic HD group showed smaller caudate and putamen volumes than the pre-symptomatic HD group (Wilk\'s Lambda = 0.80, *F*(4,57) = 3.59, *p* = .011), as previously shown by [@bb0085].

2.4. Statistical analyses {#s0040}
-------------------------

Total amygdala volumes were compared between the three groups (pre-symptomatic HD, symptomatic HD, and controls) using an analysis of variance (ANOVA) with two planned contrasts. The first contrast examined differences in total amygdala volumes between controls and both HD groups (pre-symptomatic and symptomatic HD), and the second contrast investigated differences between the pre-symptomatic and symptomatic HD groups. The association between amygdala volumes and UHDRS TMS, HADS Anxiety and Depression scores, SDMT, Stroop Word Test, UPSIT, DBS, and caudate and putamen volumes were examined in bivariate linear regression analyses. We used SPSS version 23 (SPSS Inc., Chicago, IL, USA) for all statistical analyses.

3. Results {#s0045}
==========

We found that amygdala volumes were lower in both symptomatic HD and pre-symptomatic HD compared to controls, and in symptomatic HD compared to pre-symptomatic HD. Within all groups, left and right amygdalae were non-significantly different \[control group: *F*(1,68) = 0.10, *p* = .75, pre-symptomatic HD: *F*(1,68) = 0.033, *p* = .86, symptomatic HD: *F*(1,70) = 0.052, *p* = .82\]. The effect of group membership on total amygdala volumes (as well as right and left separately) was significant (*F*(2,103) = 27.64, *p* \< .001, with a large effect size, *η*~*p*~^2^ = 0.40; [Table 2](#t0010){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}) with both pre-symptomatic and symptomatic HD participants having smaller total amygdala volumes than controls, *t*(103) = 7.34, *p* \< .001 (large effect size, *η*~*p*~^2^ = 0.34). Further, symptomatic HD participants showed smaller total amygdala volumes than pre-symptomatic HD, *t*(103) = 2.56, *p* = .012, with a small effect size, *η*~*p*~^2^ = 0.060.Fig. 1Mean total amygdala volumes for control, pre-symptomatic HD, and symptomatic HD groups. Pre-symptomatic HD and symptomatic HD participants had significantly lower amygdala volumes than control participants. Symptomatic HD participants had significantly lower amygdala volumes than pre-symptomatic HD participants. Two asterisks indicate a significance of *p* \< .001 and one asterisk indicates a significance of *p* \< .05.Fig. 1Table 2Amygdala volumetry for pre-symptomatic HD, symptomatic HD, and healthy controls within the total sample and age-matched sample.Table 2Hemisphere*Mean* (*SD*)95% CITotal sample Pre-symptomatic HDR979.90 (129.59)\[927.36, 1032.43\]L974.27 (129.01)\[924.75, 1032.79\]Total1954.17 (235.65)\[1860.58, 2047.76\] Symptomatic HDR895.83 (144.58)\[844.03, 947.64\]L888.41 (132.61)\[839.78, 937.24\]Total1784.24 (256.58)\[1691.97, 1876.52\] ControlsR1128.21 (189.98)\[1075.67, 1180.75\]L1142.17 (177.09)\[1092.65, 1191.69\]Total2270.38 (335.85)\[2176.80, 2363.97\]Age-matched sample Pre-symptomatic HDR986.09 (124.73)\[934.06, 1038.12\]L970.00 (121.35)\[919.92, 1020.08\]Total1956.09 (228.56)\[1863.20, 2048.99\] Symptomatic HDR913.78 (139.31)\[863.40, 964.16\]L894.61 (131.42)\[846.12, 943.10\]Total1808.39 (252.28)\[1718.45, 1898.33\] ControlsR1110.83 (163.22)\[1059.65, 1162.02\]L1138.58 (158.46)\[1089.31, 1187.85\]Total2249.41 (283.72)\[2158.03, 2340.79\][^2]

Symptomatic HD participants are naturally older than those with pre-symptomatic HD. Moreover, the controls were matched by age to the pre-symptomatic HD participants, and thus in our sample age and group are confounded. To address this confound, in a separate set of analyses, we excluded the four youngest control participants (*n* = 31 remaining), the five youngest pre-symptomatic HD participants (*n* = 30 remaining), and the five oldest symptomatic HD participants (*n* = 32 remaining; [Table 2](#t0010){ref-type="table"}). Although this sample yielded relatively less power than the analyses with the full sample, analyses of this age-matched subset indicated that the group effect remained statistically significant for the amygdala volumes (*F*(2,90) = 24.09, *p* \< .001, large effect, *η*^2^ = 0.34). The pattern of differences between the groups in total amygdala volumes was unchanged with smaller volumes in pre-symptomatic HD and in symptomatic HD than controls, (*t*(90) = 6.83, *p* \< .001, large effect size, *η*^2^ = 0.34), and smaller volumes in symptomatic HD than pre-symptomatic HD (*t*(90) = 2.27, *p* = .026, small effect size, *η*^2^ = 0.054). By combining the unmatched and age-matched approaches, we suggest that the differences in amygdala volumes between the three groups were not attributable to age.

We found that smaller total amygdala volumes were associated with worse motor signs (UHDRS TMS scores) and poorer cognitive performances (SDMT and Stroop Word Test scores) in pre-symptomatic and symptomatic HD participants ([Table 3](#t0015){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}). Amygdala volumes were not associated with odour recognition (UPSIT scores), or psychiatric symptoms (HADS scores), although both results suggested statistical trends. Finally, disease burden (i.e. DBS), and caudate and putamen volumes were also not significantly associated with amygdala volumes.Fig. 2UHDRS TMS (A), SDMT Scores (B), and Stroop Word Test (C) scores across total amygdala volumes for pre-symptomatic and symptomatic HD participants. Smaller amygdala volumes are associated with higher levels of motor signs (*p* \< .05), and worse cognitive performance (*p* \< .05).Fig. 2Table 3Inferential statistics for the relationship between amygdala volumes and clinical measures and measures of disease pathology in HD participants.Table 3BSE*tpη*^2^95% CIUHDRS TMS−7.472.26−3.31.001[⁎⁎](#tf0005){ref-type="table-fn"}0.14\[−11.98, −2.97\]SDMT5.702.312.47.016[⁎⁎](#tf0005){ref-type="table-fn"}0.081\[1.09, 10.32\]Stroop Word Test3.081.362.27.026[⁎⁎](#tf0005){ref-type="table-fn"}0.070\[0.38, 5.78\]UPSIT4.754.431.07.290.016\[−4.09, 13.58\]HADS Anxiety6.9911.060.63.530.006\[−15.09, 29.06\]HADS Depression−11.3514.30−0.79.430.009\[−39.87, 17.18\]Disease burden score−0.700.37−1.92.0590.051\[−1.43, 0.029\]Right caudate−19.4116.72−1.16.250.023\[−52.89, 14.08\]Left caudate25.3716.641.53.130.039\[−7.95, 58.70\]Right putamen−14.3519.06−0.75.460.010\[−52.52, 23.83\]Left putamen3.7718.210.21.840.001\[−32.69, 40.24\][^3][^4]

Psychiatric symptoms are thought to occur in HD before clinical diagnosis, and in order to asses if the amygdala is related to these symptoms we analysed the pre-symptomatic cohort further. We divided the pre-symptomatic HD group into far and close to estimated disease onset, using a median of 9.66 years to diagnosis. We found that in the close to onset group, lower total amygdala volumes were associated with greater anxiety symptoms and worse motor signs ([Table 4](#t0020){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}). In contrast, in the far from onset group of pre-symptomatic HD participants, amygdala volumes were not associated with any clinical measures. Amygdala volumes were not associated with odour recognition or cognitive performance in either group.Fig. 3UHDRS total motor scores (A) and HADS anxiety scores (B) across total amygdala volumes for pre-symptomatic HD participants close to disease onset and far from disease onset. For pre-symptomatic participants who were close to disease onset, smaller amygdala volumes were associated with higher levels of motor signs and increase in anxiety symptoms (*p* \< .05).Fig. 3Table 4Inferential statistics for the relationship between amygdala volumes and clinical measures in pre-symptomatic HD participants divided into close and far from disease onset.Table 4BSE*tpη*^2^95% CIClose to onsetUHDRS TMS−80.6035.47−2.27.041[⁎⁎](#tf0010){ref-type="table-fn"}0.28\[−157.22, −3.97\]SDMT9.396.501.45.170.13\[−4.55, 23.33\]Stroop Word Test3.573.151.13.280.079\[−3.15, 10.92\]UPSIT−13.519.35−1.45.170.13\[−33.57, 6.55\]HADS Anxiety−46.7921.08−2.22.045[⁎⁎](#tf0010){ref-type="table-fn"}0.28\[−92.33, −1.25\]HADS Depression36.7224.231.52.150.15\[−15.61, 89.06\]  Far from onsetUHDRS TMS−73.4769.24−1.06.310.074\[−221.98, 75.03\]SDMT−5.636.75−0.83.420.044\[−20.02, 8.76\]Stroop Word Test−4.903.00−1.63.120.14\[−11.26, 1.47\]UPSIT9.2214.650.63.540.026\[−22.01, 40.44\]HADS Anxiety0.5821.740.027.980.00\[−46.04, 47.20\]HADS Depression−1.7823.02−0.077.940.00\[−51.16, 47.60\][^5][^6]

4. Discussion {#s0050}
=============

In this study, we showed cross-sectional evidence that volume loss in the amygdala begins in HD before clinical diagnosis and occurs to a greater extent after diagnosis, and that this volume loss is related to motor, cognitive, and psychiatric signs. To the best of our knowledge, this is the first study in HD to directly compare amygdala volumetry between pre-symptomatic and symptomatic participants and demonstrate an association between amygdala atrophy and clinical symptomatology across the different disease stages. Our results reinforce the importance of extra-striatal structures in the clinical manifestation of HD.

A direct comparison of brain volume loss between pre-symptomatic and symptomatic HD is complex because of the expected differences in age and disease status. Nonetheless, our sub-analysis of an age-matched sample yielded the same pattern of results as the non-age matched groupings, suggesting that the findings of amygdala volume decrements in early HD cannot be explained by the older age of the group. Our findings clearly support the idea that HD exerts a detrimental effect on brain areas outside the striatum (cortical areas: [@bb0195]; thalamus: [@bb0110]; and hippocampus: [@bb0020]), including the amygdala ([@bb0040]; [@bb0060]; [@bb0115]), which begins early in the disease.

Our measures of amygdala volumes were not statistically associated with measures of disease reported in the IMAGE-HD study, including disease burden scores, and the size of the caudate nucleus and putamen ([@bb0045]; [@bb0085]; [@bb0050]). A lack of an association between amygdala volumes and measures of disease is somewhat surprising considering that striatal degeneration is thought to predict or strongly associate with many clinical and neurological signs of HD, including with deficits related to amygdala function. As an example is a recent functional MRI study that found an association between reduced anger-selective activation in the amygdala and smaller dorsal striatum volumes in pre-symptomatic HD ([@bb0215]). The lack of association observed in our study may be explained by the different rates of volume loss in amygdala versus striatal structures during the course of HD. The amygdala was approximately 7.6% smaller in symptomatic HD than pre-symptomatic HD, while the caudate and putamen were approximately 17.7% and 10.3% smaller in symptomatic HD than pre-symptomatic HD (see [Fig. 4](#f0020){ref-type="fig"}), as shown in the IMAGE-HD study ([@bb0045]; [@bb0085]; [@bb0050]). Furthermore, the different rates of volumes loss in the amygdala and striatal structures may also explain the lack of an association between amygdala volumes and disease burden scores, because disease burden scores are strongly linked to striatal pathology in HD ([@bb0150]).Fig. 4Mean caudate, putamen, and amygdala volumes for pre-symptomatic and symptomatic HD participants. At a scale of 1000 mm^3^, the difference between pre-symptomatic and symptomatic HD participants in caudate and putamen volumes (decrease of 17.7% and 10.3%, respectively) is larger than the difference in amygdala volumes (decrease of 7.6%).Fig. 4

In contrast, we did observe a relationship between the size of the amygdala and the degree of motor signs, in which smaller amygdala volumes were related to greater levels of motor signs. This relationship was dependent on proximity to disease onset: smaller amygdala volumes were related to worse motor signs in pre-symptomatic HD participants who were estimated to be close to disease onset, but not in those who were estimated to be far from disease onset. Atrophy in the striatum ([@bb0045]) and in primary motor and sensorimotor cortices ([@bb0040]) has previously been shown to be associated with motor signs. IMAGE-HD is the first study to demonstrate an association between atrophy in the amygdala and motor signs.

In addition to the association with motor signs, we found a relationship between amygdala volumes and cognitive signs. In this relationship, smaller amygdala volumes were associated with worse visuomotor skills and slower processing speed, which are the two cognitive outcomes that demonstrate HD related changes most sensitively ([@bb0185]). Previously, other cognitive signs, specifically deficits in emotion recognition, were shown to be associated with amygdala volumetry in HD ([@bb0115]). We also found a trend for associations with neuropsychiatric signs, with smaller amygdala volumes being associated with higher levels of anxiety and depressive symptoms. Assessing our pre-symptomatic HD group further, we found an association between smaller amygdala volumes and greater anxiety symptoms in pre-symptomatic HD participants who were nearing estimated disease onset. Previously, research has shown that psychiatric symptoms, particularly anxiety symptoms, begin subtly in the pre-symptomatic phase and continue to peak with worsening motor signs ([@bb0065]). Our findings extend on the current literature by showing that the amygdala is related to the increase in anxiety symptoms seen in the stage close to clinical diagnosis.

Amygdala volumes were not associated with odour recognition, despite known associations between the amygdala and olfactory processing ([@bb0130]; [@bb0165]; [@bb0175]). In our sample, pre-symptomatic and symptomatic HD participants scored similarly on the UPSIT and within a narrow range, so we would not have expected to see associations within our dataset ([@bb0085]).

5. Conclusions {#s0055}
==============

In conclusion, this study provides findings that are important to understanding how abnormalities in extra-striatal structures, in addition to degeneration in striatal and cortical areas, may contribute to the manifestation of HD in the years before onset of clinical symptoms and across the disease. Furthermore, our work highlights the need for the brain in HD to be considered as a unified whole, rather than separate structures and areas targeted individually by HD.

We acknowledge the contribution of all the participants who took part in the IMAGE-HD study. We thank the Royal Children\'s Hospital for the use of their 3 T MR scanner. The IMAGE-HD study was supported by the CHDI Foundation Inc. (USA), whom we thank. Dr Yifat Glikmann-Johnston is the recipient of a National Health and Medical Research Council -- Australian Research Council Dementia Research Development Fellowship (grant number 1100862) funded by the Australian Government.

[^1]: Abbreviations. UHDRS TMS = Unified Huntington\'s Disease Rating Scale total motor score. HADS = Hospital Anxiety and Depression Scale. DBS = disease burden score.

[^2]: Abbreviations. R = right amygdala. L = left amygdala. Total = right + left amygdala. CI = confidence interval.

[^3]: Abbreviations. B = unstandardised regression coefficient. SE = standard error. CI = confidence interval. UHDRS TMS = Unified Huntington\'s Disease Rating Scale Total Motor Score. SDMT = Symbol Digit Modalities Test. UPSIT = University of Pennsylvania Smell Identification Test. HADS = Hospital Anxiety and Depression Scale.

[^4]: *p* \< .05.

[^5]: Abbreviations. B = unstandardised regression coefficient. SE = standard error. CI = confidence interval. UHDRS TMS = Unified Huntington\'s Disease Rating Scale Total Motor Score. SDMT = Symbol Digit Modalities Test. UPSIT = University of Pennsylvania Smell Identification Test. HADS = Hospital Anxiety and Depression Scale.

[^6]: *p* \< .05.
